Investigating a protein as a potential treatment for T-cell lymphomas
Role of Heat Shock Protein 70 as a Mediator and Therapeutic Target in T-cell Lymphomas
This study is looking at a special protein called HSP70 that is found in higher amounts in certain types of T-cell lymphomas, like peripheral T-cell lymphoma and cutaneous T-cell lymphoma, and is testing a new treatment that uses targeted antibodies to help fight these cancers more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10886060 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of Heat Shock Protein 70 (HSP70) in T-cell lymphomas, specifically peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). The researchers have identified HSP70 as a promising target due to its high expression in cancerous cells compared to normal T-cells. They are developing a targeted therapy using monoclonal antibodies linked to a potent drug to selectively attack and inhibit the growth of these lymphoma cells. This approach aims to improve treatment outcomes for patients with these aggressive forms of cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with peripheral T-cell lymphoma or cutaneous T-cell lymphoma, particularly those who have not responded well to existing therapies.
Not a fit: Patients with B-cell lymphomas or those who do not have T-cell lymphomas may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from T-cell lymphomas, potentially improving survival rates.
How similar studies have performed: While there has been significant progress in treating B-cell lymphomas, this approach targeting HSP70 in T-cell lymphomas is relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Orlowski, Robert Zygmunt — University of Tx Md Anderson Can Ctr
- Study coordinator: Orlowski, Robert Zygmunt
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.